Bysanti FDA Approval for Bipolar I and Schizophrenia Marks Vanda’s Second Win in Two Months
Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone) to treat acute manic or mixed episodes of bipolar I disorder and schizophrenia in adults. The approval introduces a new chemical entity in the atypical antipsychotic class that is bioequivalent to Vanda’s existing drug Fanapt and converts to iloperidone in the body. Bysanti is slated for U.S. launch in Q3 2026, with patent protection through 2044 and a concurrent trial exploring its use in treatment‑resistant depression. The decision follows Vanda’s recent approval of Nereus and lifts the company’s 2025 revenue to $216 million, with 2026 guidance of $230‑$260 million.
Early Add-On Therapy Associated With Strong Clinical Response in MG
A multicenter retrospective registry of 153 AChR‑positive generalized myasthenia gravis patients found that initiating add‑on immunotherapy within 24 months of diagnosis (early intensified treatment) produced faster and larger improvements in MG‑ADL, QMG, and quality‑of‑life scores than later escalation. Early patients...
J&J Commits $1B to Next-Gen Cell Therapy Manufacturing in Pennsylvania
Johnson & Johnson announced a more than $1 billion investment to build a next‑generation cell and gene therapy manufacturing complex on a 154‑acre site in Montgomery County, Pennsylvania. Construction is slated to start in the second half of 2026, creating over...
Rethinking Idiopathic Pulmonary Fibrosis: Unmet Needs, Evolving Biology and the Future of Clinical Research
Idiopathic pulmonary fibrosis (IPF) continues to pose a severe, often late‑diagnosed respiratory challenge, with mortality exceeding many cancers. Boehringer Ingelheim’s Martin Beck highlighted the shift toward earlier detection using AI‑enhanced imaging and a broader view of IPF as a heterogeneous,...
Water Interactions Reveal How Surface Coatings Reshape Nanoparticle Drug Delivery
Arizona State University researchers quantified how water interacts with biomolecule‑coated magnetite nanoparticles, revealing that surface coatings dramatically reshape hydration energetics, immune recognition, and drug‑delivery performance. Using a calorimetry‑gas adsorption system, they measured water adsorption on particles coated with bovine serum...
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug
Generate Biomedicines priced its IPO at $16 per share, raising $400 million to fund pivotal trials of its lead candidate GB‑0895. The antibody blocks the TSLP pathway and is engineered for six‑month dosing, a potential advantage over existing asthma biologics that...
Computer Run on Human Brain Cells Learned to Play ‘Doom’
Cortical Labs in Australia has upgraded its biocomputer, built from lab‑grown human neurons, to play the first‑person shooter *Doom*. The new CL1 platform translates visual game data into electrical stimulation patterns that the neuronal network can interpret, achieving adaptive, real‑time...
$24M Verdict Against Seattle Stem Cell Center Clinic in Man’s Death
Seattle Stem Cell Center was ordered to pay $24 million after a jury found the clinic liable for the 2019 death of Michael Trujillo, who suffered catastrophic bleeding following an undocumented epidural injection while on blood‑thinning medication. Evidence showed the procedure...
BioAtla Axes 70% of Staff, Explores Strategic Options
BioAtla announced it is slashing roughly 70% of its staff as it evaluates strategic alternatives, leaving only essential personnel for the review. The move follows a 30% reduction last year and leaves the company with about $7.1 million in cash, down...
The Relevance of Clonal Hematopoiesis to Degenerative Aging Remains Uncertain
Clonal hematopoiesis (CH) is the age‑related expansion of blood‑cell clones carrying somatic mutations acquired in hematopoietic stem cells. Detectable CH appears in roughly 10 % of individuals over 70, making it a common form of somatic mosaicism. While CH is a...
Simulations of Your Gut May Predict Which Probiotics Will Stick
Researchers have built microbial community‑scale metabolic models that simulate how specific probiotic strains behave in an individual’s gut. Using baseline microbiome data, the models predicted engraftment with 75‑80% accuracy and linked bacterial growth to health outcomes such as improved post‑meal...
CollPlant Targets Formulation Bottleneck with New DLP Bioprinting Kit
CollPlant has introduced BioFlex, a ready‑to‑print DLP bioprinting kit built on recombinant human collagen and a biodegradable polymer. The kit includes pre‑validated photo‑active agents and detailed formulation guidelines, aiming to cut bioink development time for tissue‑modeling and organ engineering. By...
Alnylam Canada ULC – Receives Positive Recommendation From Canada’s Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (Vutrisiran Injection),...
Alnylam Canada received a positive recommendation from Canada’s Drug Agency to list AMVUTTRA® (vutrisiran) for public reimbursement in adult patients with cardiomyopathy caused by wild‑type or hereditary ATTR amyloidosis. The therapy, approved by Health Canada in December 2025, expands the...
Moderna’s Dual Covid-Flu Vaccine Poised for EMA Approval on Positive CHMP Take
The European Medicines Agency’s CHMP has issued a positive opinion on Moderna’s mCombriax, a combined COVID‑19 and influenza mRNA vaccine, after a Phase III trial showed stronger immune responses than a mixed regimen of Sanofi’s flu shot and Spikevax. EMA approval...
Other News to Note for March 2, 2026
At CROI 2026, researchers spotlighted the growing neurodegenerative burden among aging people living with HIV, emphasizing heightened risks of depression and cognitive vulnerability despite long‑term antiretroviral therapy. Parallelly, the University of Southern California announced a novel series of MAPT aggregation...
In the Clinic for March 2, 2026
BioWorld’s “In the Clinic for March 2, 2026” page functions as a centralized gateway to the latest biopharma, med‑tech, and scientific content. It aggregates data snapshots, special reports, infographics, and market scorecards covering everything from GLP‑1 trends in China to mRNA vaccine...
Regulatory Actions for March 2, 2026
On March 2, 2026 BioWorld published a regulatory snapshot covering biopharma and med‑tech firms such as AS Software, Asieris, Boehringer Ingelheim, Deephealth, Eli Lilly, Ipsen, Moderna, Neurogene, Novartis, Optellum, Photocure, Regeneron, Sanofi, Sentynl, Synergy Spine Solutions and X4. The roundup highlights...
Where Life Science Meets Litigation
In this episode of Inside Biotech, host Karish Manchugani chats with Tim Dabrowski, a Berkeley‑trained patent attorney at Mintz, about his unconventional path from a physiology degree to biotech IP law. Tim explains how his scientific background informs his work...
INN-Coming: Insights on the Industry’s Latest Disclosures
The WHO’s INN proposed list 134, released in early 2026, reveals several late‑stage drug candidates that were previously hidden from public view. Notably, two NLRP3 inhibitors—abdenoflast and parunoflast—appear to map to Eli Lilly’s newly acquired Ventyx assets VTX2735 and VTX3232, both showing promising...
Newfound Third Cell Type Enables Fully Functional Hair Follicles in the Lab
Researchers identified a previously unknown accessory mesenchymal cell (PDGFRα⁺/Sca1⁺/CD34⁺) that enables complete hair follicle formation in a dish. By integrating this cell type with epithelial stem cells and dermal papilla cells, they created a three‑cell organ germ that grew downward,...
Ribosomes in Pairs: A Survival Strategy Inside Stressed Cells
Scientists at the Max Planck Institute have identified a novel RNA‑driven mechanism that pairs inactive ribosomes into disomes when animal cells, including neurons, face nutrient starvation or temperature stress. The pairing is mediated by a specific ribosomal RNA expansion segment,...
Researchers Create World's Largest Dog and Cat Tumor Database
Researchers from the University of Liverpool and the University of Las Palmas de Gran Canaria have launched the world’s largest open‑source tumor database for dogs and cats, containing over one million records. The registry covers more than 200 breeds and...
Ozempic Reverses Osteoarthritis Cartilage Damage, Study Shows
I used to teach that osteoarthritis was "wear and tear" — lose weight, take painkillers, wait for a knee replacement. A study just published in Cell Metabolism proved that wrong. Semaglutide (Ozempic) didn't just reduce joint pain in osteoarthritis patients — it...
Bioxytran Reports Positive Phase 1b/2a Results for Antiviral ProLectin‑M
Bioxytran announced positive phase 1b/2a data for its oral antiviral ProLectin‑M in a randomized, double‑blind, placebo‑controlled trial of 39 mild‑to‑moderate COVID‑19 patients in India. The highest dose (16,800 mg/day) achieved viral clearance in 90% of participants by day 5 versus 20% on placebo,...
Module 2, Section 2: The Druggable Interactome
The Module 2, Section 2 lecture introduces the druggable interactome, compiling key resources that map the human druggable genome, protein expression, kinase families, transcription‑factor proteomics, GPCRs, and ion‑channel complexes. It highlights quantitative estimates—over 3,000 proteins deemed druggable and hundreds of actionable kinases—while...
Vueway Expands Pediatric Use: Alberto Spinazzi Shares Bracco Group’s Vision
The European Union has granted approval for Vueway (gadopiclenol) to be used in neonates, infants, and toddlers, marking a pivotal expansion of pediatric MRI contrast agents. Vueway delivers diagnostic‑grade imaging at half the dose of conventional macrocyclic GBCAs, thanks to...
Safety Concerns Spur Aardvark to Halt Key Prader-Willi Drug Trial
Biotech Aardvark Therapeutics announced a voluntary pause of the Phase 3 HERO trial for its Prader‑Willi drug ARD‑101 after routine safety monitoring identified reversible cardiac observations in healthy volunteers receiving supratherapeutic doses. The pause affects both the main trial and an...
Advocacy Bias Keeps Unproven DMD Therapy, Blocks HD Progress
The Duchenne muscular dystrophy patient & advocacy community keeps a gene therapy and multiple drugs on the US market, stopping the FDA from taking action, despite failed confirmatory clinical trials showing no efficacy and questionable safety. The Huntington's disease patient and...
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
Merck and Pfizer’s Keytruda‑Padcev doublet delivered a dramatic survival advantage in the Phase 3 EV‑304 study of muscle‑invasive bladder cancer. The regimen cut the risk of disease progression, recurrence or death by 47% compared with gemcitabine‑cisplatin and lowered overall‑mortality risk by...
Best Practices for Applying HDX-MS to FBLD
A recent open‑access study demonstrates that hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) can reliably map binding sites of extremely weak fragment hits (up to 7 mM KD) against Cyclophilin D. By optimizing protein concentration at 10 µM and testing fragments at 2.5‑10 mM, the...
Big Pharma’s Next Entrant Could Come From China
Chinese drugmakers, led by Jiangsu Hengrui Pharmaceuticals, are emerging as global biotech contenders. Hengrui topped 2024 trial sponsorship, boasts a pipeline of 100 investigational drugs and 400 trials, and secured a $500 million partnership with GSK that could yield $12 billion. Analysts...
FDA Demands Sham‑controlled Trial for uniQure’s AMT‑130
$QURE AMT-130 update: Still blocked The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for...
P‑tau 217 Blood Test Outperforms Total P‑tau 217 For
The breakthrough blood test p-tau 217 for risk and diagnosis of Alzheimer's disease is more accurate than total p-tau 217, in a head-to-head comparison using PET imaging https://t.co/faILpVr9Ua https://t.co/lzUgFnFUP5
Gene Therapy’s Inflexion Point: From Scientific Breakthrough to Systemic Transformation
Gene therapy for sickle cell disease has moved from experimental promise to an actionable clinical reality, with early CRISPR‑based treatments already cutting crises and hospital stays. A recent Sanius Health survey of 94 patients shows strong interest—71% want more information—yet...
GLP‑1 Weight‑Loss Drugs Work Better for Women
A systematic RCT analysis of GLP-1 drugs show they are more effective in women than men for weight loss https://t.co/cycwi4nnN5 https://t.co/KOl0FgKaZD
Roche's MS Drug Shows Promise, Approval Still Uncertain
Roche pill succeeds in another MS study, but approval questions linger https://t.co/JY8uZCI5iA @ByJonGardner $RHHBY $SNY
FDA Demands Extra Study for UniQure's Huntington Gene Therapy
UniQure says FDA wants another study of Huntington’s gene therapy https://t.co/1pgFDoE2V9 by @realJacobBell $QURE - 35% #GeneTherapy #Huntingtonsdisease
Biologists Using AI Will Outpace Those Who Don't
1/ AI won't replace you. But a biologist who uses AI will. Especially in bioinformatics, where the questions never stop coming. https://t.co/q2OHzntcoV
AI Pathology for Cancer Markers Hindered by Shortcut Learning
AI of whole slide images for cancer molecular markers is not ready for clinical use due to confounding and biases ("shortcut learning"), supported by multiple examples @natBME https://t.co/zG8uVIxrJf https://t.co/hQ0tjiapIJ
Exercise‑derived Muscle Vesicles Boost Brain Microglia, Improve Cognition
A new mechanism for improved cognitive function from exercise in the Alzheimer's disease model Skeletal muscle EC vesicles interact with the brain and rev up microglia function https://t.co/eZu14YVasY
Aardvark Pauses Pivotal Prader‑Willi Trial over Safety
Safety concerns spur Aardvark to halt key Prader-Willi drug trial https://t.co/PWkOuDMIvo $AARD - 52% $SLNO
Vaccine Pioneer Warns: We’re Heading Downhill.
Stanley Plotkin, known as the “godfather of vaccines,” in an interview with @HelenBranswell: “All I can say is that I’m beginning to regret having lived so long — because we’re going downhill.” https://t.co/A2zcoP2Ghd
Antibody Plus Ozempic Drives Significant Weight Loss
New @NatureMedicine A randomized trial of antibody vs activin type II receptors with or without semaglutide (Ozempic). The antibody, bimagrumab, promotes muscle growth. Marked weight loss with the combination https://t.co/XUK93GTAmA
Veteran Vaccine Pioneer Warns of Eroding Confidence
Stanley Plotkin had a major hand in the development of a number of vaccines in use today; he designed the rubella vaccine. He remembers the world before widespread use of vaccines & knows what's coming as vaccine policy is rewritten...
GENB CEO Describes Emotional Whirlwind Going Public
2March: How did @generate_biomed CEO @mike_nally describe his whirlwind of emotions as his company went public? Read what he and CFO Jason Silvers, MD, JD said about $GENB plus updates on $CASIF, $NVAX, $PMVP & $SRPT in my latest StockWatch...
Future: Real-Time Immune Monitoring Like Glucose Tracking
Someday we'll be able to track our immune system like we do glucose Today @NatBME https://t.co/HFcFiUeyFg Previously @ScienceMagazine https://t.co/EcgBdwGxcd https://t.co/SpoZ5bLtjx
Flare's GU26 Targets Undruggable PPAR‑γ, Yet Caveats Remain
Who's heard of Flare Therapeutics? #GU26 late-breaker shows promise in hitting "undruggable" PPAR-γ target, with a few major caveats. Via @ApexOnco -> https://t.co/1GepvywtL0
BiotechTV Welcomes New Contributor Wassim Laroussi
BiotechTV is growing today. I’m happy to welcome @WassimLaroussi3 as our newest contributor. I’ve been impressed with his own videos, and he is going to do some very cool stuff for @BiotechTV. https://t.co/LUcm1sTqGz
FDA Limits NTLA Gene Therapy to Mild Cases, Undermining Demand
$NTLA drug is off hold but now being restricted by the FDA to the least severe/sick patients, which would logically be those least likely to want/need an experimental gene editing therapy. Existing options will dominate. Target/disease selection is a...
MRK's Ovarian Cancer Claim Rejected by FDA, EMA
$MRK claims a survival benefit in ovarian cancer irrespective of PD-L1 status, but FDA & EMA say BS. Via @ApexOnco -> https://t.co/Cld1O7Uuvp #ESGO26